MediciNova, Inc.
NASDAQ:MNOVBiotechnology
-$0.02 today
- Market cap
- $68.14M
- Beta
- 0.62
- P/E (TTM)
- -5.6
- EPS (TTM)
- -$0.24
Volume 0.12M
Average 0.04M
MNOV Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
MediciNova, Inc.NASDAQ: MNOV
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $44.81K rose 765.6% year over year, ahead of the -109.9% change in trailing-twelve-month depreciation & amortization. Over 3 fiscal years it compounded at +4.3% a year.
Context
- Depreciation & amortization amounted to 4.9% of revenue in FY2025.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +765.6% holds above the trailing-twelve-month pace of -109.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 20.1K USD
- Year-over-year change
- -4.6%
- 4-year CAGR
- -6.4%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 20.1K | -4.6% |
| FY2024 | 2024-12-31 | 21.08K | +3.9% |
| FY2023 | 2023-12-31 | 20.3K | +14.6% |
| FY2022 | 2022-12-31 | 17.71K | -32.3% |
| FY2021 | 2021-12-31 | 26.15K | — |
Depreciation & Amortization vs competitors
How MNOV compares with its peers on the latest reported figures
- MNOV's LTM Mar 2026 depreciation & amortization of -$2.07K is the lowest of the 11 companies compared; the peer median is $1.48M.
- Its year-over-year change of -109.9% is the lowest of 11, against a peer median of -18.1%.
- Depreciation & amortization amounts to 0.3% of revenue for MNOV, versus a peer median of 19.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.46M | -16.4% | +13.9% | 2.9% | |
CBUSCibus, Inc. | LTM Mar 2026 | $5.49M | -17.8% | +56.9% | 128.0% |
| LTM Mar 2026 | $5.17M | -29.3% | -20.7% | 7.8% | |
| LTM Mar 2026 | $2.88M | -18.4% | -17.7% | 31.5% | |
| LTM Mar 2026 | $1.58M | -10.2% | -13.6% | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $1.39M | +27.4% | +55.0% | — |
| LTM Mar 2026 | $1.02M | -43.2% | +26.8% | — | |
| LTM Mar 2026 | $158K | +4.6% | +29.7% | — | |
| LTM Mar 2026 | $130K | -84.1% | -41.1% | — | |
| LTM Mar 2026 | $0 | -100.0% | — | — | |
| LTM Mar 2026 | -$2.07K | -109.9% | +4.3% | 0.3% | |
| Peer median (excluding MNOV) | $1.48M | -18.1% | +13.9% | 19.7% | |
Competitors are the stored peer set for MNOV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.04M | 0 | 1M | 0 | 409.66K |
| Cost of Revenue | 0 | 0 | 0 | 0 | 378.61K |
| Gross Profit | 4.04M | 0 | 1M | 0 | 31.05K |
| Gross Margin | 100.0% | — | 100.0% | — | 7.6% |
| Research & Development | 8.1M | 9.14M | 5.66M | 7.2M | 7.15M |
| Selling, General & Admin | 5.72M | 5.48M | 5.24M | 5.48M | 6.16M |
| Operating Expenses | 14.25M | 14.63M | 10.9M | 12.68M | 13.31M |
| Depreciation & Amortization | 26.15K | 17.71K | 20.3K | 21.08K | 20.1K |
| EBITDA | (10.11M) | (14.05M) | (8.55M) | (11.02M) | (11.97M) |
| EBITDA Margin | -250.3% | — | -854.8% | — | -2922.4% |
| Operating Income | (10.22M) | (14.63M) | (9.9M) | (12.68M) | (13.28M) |
| Operating Margin | -253.0% | — | -990.0% | — | -3242.5% |
| Interest Income | 143.63K | 809.67K | 1.83M | 1.67M | 1.3M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 84.13K | 562.39K | 1.33M | 1.63M | 1.29M |
| Income Before Tax | (10.13M) | (14.07M) | (8.57M) | (11.04M) | (11.99M) |
| Pre-Tax Margin | -250.9% | — | -856.8% | — | -2927.3% |
| Income Tax Expense | 2.57K | 2.82K | 3.05K | 5.54K | 5.99K |
| Net Income | (10.13M) | (14.07M) | (8.57M) | (11.05M) | (12M) |
| Net Margin | -251.0% | — | -857.2% | — | -2928.8% |
| EPS (Basic) | (0.21) | (0.29) | (0.17) | (0.23) | (0.24) |
| EPS (Diluted) | (0.21) | (0.29) | (0.17) | (0.23) | (0.24) |
| Weighted Avg Shares | 48.6M | 49.05M | 49.05M | 49.05M | 49.06M |
| Weighted Avg Shares (Diluted) | 48.6M | 49.05M | 49.05M | 49.05M | 49.06M |
MediciNova, Inc.
NASDAQ:MNOV
Intrinsic Alpha fair value
Locked
Current Price
$1.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.